Sun Pharma Share Price
(SUNPHARMA)
₹1665.7
as on 01:36PM, 20 Feb 2025
Sun Pharma Performance
Day's Low
Day's High
₹1,663Day's Price Range₹1,677.9552 Week's Low
52 Week's High
₹1,377.252-Week Price Range₹1,960.35
| Returns % | |
| 1 Month Return | -5.72 % |
| 3 Month Return | -5.81 % |
| 1 Year Return | + 8.96 % |
| Market Stats | |
| Previous Close | ₹1,676.60 |
| Open | ₹1,665.90 |
| Volume | 25.76L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹4,02,272.50Cr |
Sun Pharma Key Statistics
P/E Ratio
35.15
PEG Ratio
3.32
Market Cap
₹4,02,272.50 Cr
P/B Ratio
16.41
EPS
40.21
Dividend Yield
0.83
Sector
Pharmaceuticals
ROE
12.05
Sun Pharma Mutual Fund Holdings
Sun Pharma Analyst Rating
based on 37 analysts
78.38%
Buy
13.51%
Hold
8.11%
Sell
Based on 37 analysts offering long term price targets for Sun Pharma. An average target of ₹2076.97
Source: S&P Global Market Intelligence
Sun Pharma Share analysis
Sun Pharma price forecast by 37 analysts
Upside of23.88%
High
₹2450
Target
₹2076.97
Low
₹1625
Sun Pharma target price ₹2076.97, a slight upside of 23.88% compared to current price of ₹1665.7. According to 37 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Sun Pharma revenue growth forecast
Expected growth rate Q1, FY2027:31.91%
Forecast
Actual
Including amortisation and stock based compensations
Sun Pharma EPS growth forecast
EPS estimate Q1, FY2027:56.18%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Sun Pharmaceuticals Industries Ltd
Vidhi Shanghvi: Rising Star at Sun Pharmaceuticals - 20 Feb, 2025
Vidhi Shanghvi, daughter of pharma billionaire Dilip Shanghvi, is Vice President at Sun Pharmaceuticals. She leads Consumer Healthcare and Nutrition, showcasing her significant role in the company.Sun Pharma Shares Decline Amid Market Activity - 19 Feb, 2025
On February 19, 2025, Sun Pharmaceuticals experienced a decline in share price, opening lower and falling over 3% during trading. The company is expected to face minimal impact from US generics sales due to low dependency.Sun Pharma Faces Challenges Amid Sustainability Recognition - 17 Feb, 2025
Sun Pharmaceuticals faced a challenging market environment with declining stock performance, pricing pressures, and net losses, but received recognition in sustainability efforts. The company is also set to discuss growth strategies at an upcoming summit.Sun Pharma Confident Amid US Tariff Concerns - 16 Feb, 2025
Sun Pharmaceutical's MD, Dilip Shanghvi, expressed confidence regarding potential US tariffs on pharma imports, suggesting that costs could be passed to customers. He emphasized the company's strong position and ability to adapt to regulatory changes, highlighting its diversified global presence and focus on specialty products.Sun Pharma Considers Business Split for Growth - 15 Feb, 2025
Dilip Shanghvi, Founder of Sun Pharma, indicated plans to split the business into verticals, anticipating faster growth in specialty and branded generic segments.Sun Pharma Faces Tariff Pressures, Analyst Optimistic - 14 Feb, 2025
Sun Pharmaceuticals is currently priced at ₹1,746, with a suggested buy range. Analysts warn of tariff impacts but still favor Sun Pharma as a strong choice.Bearish Sentiment Surrounds Sun Pharmaceutical Stocks - 12 Feb, 2025
Sun Pharmaceutical Industries Ltd faces bearish momentum as pharma stocks decline. Analysts suggest a short position due to weakness in RSI indicators.Pharma Stocks Decline Amid Tariff Concerns - 10 Feb, 2025
On February 10, 2025, concerns regarding possible tariffs on pharma imports by US President Trump led to a decline in pharma stocks, including Sun Pharma Advanced Research, which has lost significant value from its 52-week highs.Sun Pharma Faces GST Penalty Amid Leadership Changes - 04 Feb, 2025
Sun Pharmaceuticals appointed Aalok Shanghvi as COO, reaffirmed a target price of Rs 2,275, and acknowledged a ₹160 crore GST penalty with no expected financial impact.Sun Pharma Announces Dividend and Leadership Changes - 03 Feb, 2025
Sun Pharma declared a Rs 10.50 dividend per share, reported positive Q3 performance, and elevated Aalok Shanghvi to COO. JM Financial sees 20.1% upside.Sun Pharma Declares Dividend Ahead of Ex-Dividend Date - 02 Feb, 2025
Sun Pharmaceutical Industries Ltd has announced a dividend of ₹10.5 per share, with February 6 designated as the record date for shareholders.Sun Pharma Reports Strong Q3FY25 Financial Results - 31 Jan, 2025
Sun Pharmaceutical Industries posted a 15% increase in net profit and a 10.5% rise in revenue for Q3FY25, driven by domestic sales and new product launches. Despite a slight decline in US sales, overall growth remains strong, particularly in emerging markets and active pharmaceutical ingredients.Sun Pharma Anticipates Strong Q3 Earnings Growth - 29 Jan, 2025
Sun Pharmaceuticals is projected to report a 12.7% year-on-year increase in profits and a 10% rise in revenues for Q3 FY25, driven by strong domestic and specialty sales despite margin pressures.Sun Pharma Faces Bearish Pressure Amid Market Decline - 28 Jan, 2025
On January 28, 2025, Sun Pharma's stock faced significant bearish momentum, breaking below crucial support levels as the Nifty Pharma index dropped nearly 3%. Analysts recommend a target of ₹1,675 with a stop-loss at ₹1,750.Analysts Forecast Steady Growth for Sun Pharma - 24 Jan, 2025
Analysts expect Sun Pharmaceuticals to sustain low-double digit EPS growth over the medium term, with trading multiples potentially ranging from 25 to 35 times forward earnings.Analysts Recommend Buying Sun Pharma Shares - 23 Jan, 2025
Market experts recommend buying Sun Pharma shares, with target prices ranging from Rs 1850 to Rs 1890, highlighting the company's strong market position and growth potential.
Insights on Sun Pharmaceuticals Industries Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTFII Holding Up
Foreign Institutions have increased holdings from 18.02% to 18.05% in Dec 2024 quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 8.89% to 8.92% in Dec 2024 quarter
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 12.11% to 12.24% in Dec 2024 quarter
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 12.58K Cr → 14.14K Cr (in ₹), with an average increase of 3.8% per quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 54.48% of holdings in Dec 2024 quarter
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 59.9% return, outperforming this stock by 50.9%
- NO EFFECT
Against Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 135.1% return, outperforming this stock by 36.4%
NEGATIVE IMPACTPrice Dip
In the last 1 month, SUNPHARMA stock has moved down by -5.7%
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 3.04K Cr → 2.90K Cr (in ₹), with an average decrease of 4.5% per quarter
News
Meet Daughter of India's Richest Pharma Billionaire and Sun Pharma VP
Vidhi Shanghvi is a well-known name in the business world. She is the Vice President at Sun Pharmaceuticals Industries Ltd, one of the largest pharma firms in India with a market cap of Rs 4.01 lakh crore. Vidhi is the daughter of pharma billionaire Dilip Shanghvi, who started Sun Pharma in 1983. He is the richest pharma man in the country with a real-time net worth of USD 26.1 billion as of February 19, as per Forbes. Her daughter Vidhi is also the Head of Consumer Healthcare and Nutrition and India Distribution of Sun Pharma. The young businesswoman has been with the company for over a decade. She is also a non-executive director of Sun Pharma Advanced Research Company Limited (SPARC), as per the companys website. It is a clinical-stage biopharmaceutical company and was formed in 2007 after a demerger from Sun Pharma. Before officially taking charge as Head of the Consumer Division, she worked with the marketing function of Sun Pharma India Business.20 Feb, 2025 05:37 AMImpact of Trump Tariffs on Indian Pharma Exports
Should tariffs be imposed, Indian companies are expected to pass on the cost to the consumers, as indicated by Indias largest drugmaker Sun Pharmas managing director Dilip Shanghvi recently at a media summit.20 Feb, 2025 05:30 AMImpact of Higher Tariffs on India's Pharma Market Competitiveness
IPA primarily represents companies specializing in producing generic drugs, which are lower-cost versions of branded medications. It is an association of 23 research-based pharma companies including Sun Pharma, Lupin. Cipla, Dr Reddys and Mankind. They contribute more than 80% of the countrys exports of drugs and pharmaceuticals and service over 64 percent of the domestic market.19 Feb, 2025 08:07 PMSun Pharma Financials
Index Inclusions
Sun Pharma Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 54.48% | 0.00 | |
| Foreign Institutions | 18.05% | 0.17 | |
| Mutual Funds | 12.24% | 1.02 | |
| Retail Investors | 8.92% | 0.33 | |
| Others | 6.31% |
Sun Pharma Key Indicators
Sun Pharma Valuation
Sun Pharma in the last 5 years
Lowest (19.47x)
March 23, 2020
Today (35.15x)
February 19, 2025
Industry (51.87x)
February 19, 2025
Highest (184.63x)
August 28, 2020
Sun Pharma Earnings and Dividends
Sun Pharmaceuticals Industries Ltd Earnings Results
Sun Pharmaceuticals Industries Ltd’s net profit jumped 15.04% since last year same period to ₹2,903.38Cr in the Q3 2024-2025. On a quarterly growth basis, Sun Pharmaceuticals Industries Ltd has generated -4.5% fall in its net profits since last 3-months.
Read More about Earnings ResultsSun Pharmaceuticals Industries Ltd Dividends January,2025
In the quarter ending December 2024, Sun Pharmaceuticals Industries Ltd has declared dividend of ₹10.50 - translating a dividend yield of 1.43%.
Read More about Dividends
Sun Pharma Technicals Summary
Bearish
Neutral
Bullish
Sun Pharmaceuticals Industries Ltd is currently in a Bearish trading position according to technical analysis indicators.
Sun Pharma Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹4,02,272.50 Cr | 62.81% | 0.68 | ₹9,648 Cr | ₹48,496 Cr | |
| HOLD | ₹1,57,552.95 Cr | 34.72% | 0.50 | ₹1,600 Cr | ₹7,845 Cr | |
| BUY | ₹1,05,608.85 Cr | 35.75% | 0.67 | ₹1,656 Cr | ₹10,727 Cr | |
| BUY | ₹40,436.21 Cr | 1.38% | 0.58 | ₹1,297 Cr | ₹14,755 Cr | |
| HOLD | ₹24,705.34 Cr | -3.52% | 0.50 | ₹772 Cr | ₹5,664 Cr |
About Sun Pharma
Sun Pharma's branded formulations include products for cardiovascular, central nervous system, gastroenterology, ophthalmology, and dermatology. Sun Pharma's specialty generics include injectables, inhalants, and complex products. Sun Pharma's API portfolio includes products for a range of therapeutic areas, including cardiovascular, central nervous system, gastroenterology, and dermatology.
Sun Pharma's top products include Modalert, a generic version of Modafinil for treating sleep disorders; Glocip, a generic version of Glipizide for treating diabetes; and Doxicip, a generic version of Doxycycline for treating bacterial infections. Sun Pharma's popular brands include Revital, a multivitamin supplement; Tazret, a topical retinoid for treating psoriasis; and Olmecip, a generic version of Olmesartan for treating hypertension.
Share Price: ₹1665.70 per share as on 20 Feb, 2025 01:36 PM
Market Capitalisation: ₹4,02,272.50Cr as of today
Revenue: ₹13,436.94Cr as on December 2024 (Q4 24)
Net Profit: ₹2,917.54Cr as on December 2024 (Q4 24)
Listing date: 08 Feb, 1995
| Organisation | Sun Pharma |
| Headquarters | Mumbai |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Sun Pharmaceuticals Industries Ltd
What is Sun Pharmaceuticals Industries Ltd price today?
Sun Pharmaceuticals Industries Ltd share price today stands at ₹1665.7, Open: ₹1665.9, Previous Close: ₹1676.6, High: ₹1677.95, Low: ₹1663, 52 Week High: ₹1960.35, 52 Week Low: ₹1377.2.
How to Buy Sun Pharmaceuticals Industries Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Sun Pharmaceuticals Industries Ltd shares
Is Sun Pharmaceuticals Industries Ltd listed on NSE?
Sun Pharmaceuticals Industries Ltd is listed on NSE
Is Sun Pharmaceuticals Industries Ltd listed on BSE?
Sun Pharmaceuticals Industries Ltd is listed on BSE
What are today's High and Low prices of Sun Pharmaceuticals Industries Ltd?
- Today's highest price of Sun Pharmaceuticals Industries Ltd is ₹1677.95.
- Today's lowest price of Sun Pharmaceuticals Industries Ltd is ₹1663.
What are today's traded volumes of Sun Pharmaceuticals Industries Ltd?
Today's traded volume of Sun Pharmaceuticals Industries Ltd(SUNPHARMA) is 25.76L.
What is today's market capitalisation of Sun Pharmaceuticals Industries Ltd?
Today's market capitalisation of Sun Pharmaceuticals Industries Ltd(SUNPHARMA) is ₹402272.5Cr.
What is the 52 Week High and Low Range of Sun Pharmaceuticals Industries Ltd?
How much percentage Sun Pharmaceuticals Industries Ltd is down from its 52 Week High?
Sun Pharmaceuticals Industries Ltd (SUNPHARMA) share price is ₹1665.7. It is down -15.03% from its 52 Week High price of ₹1960.35
How much percentage Sun Pharmaceuticals Industries Ltd is up from its 52 Week low?
Sun Pharmaceuticals Industries Ltd (SUNPHARMA) share price is ₹1665.7. It is up 20.95% from its 52 Week Low price of ₹1377.2
What are the historical returns of Sun Pharmaceuticals Industries Ltd?
What is the PE ratio of Sun Pharmaceuticals Industries Ltd today?
PE Ratio of Sun Pharmaceuticals Industries Ltd is 35.15
PE ratio = Sun Pharmaceuticals Industries Ltd Market price per share / Sun Pharmaceuticals Industries Ltd Earnings per share